To save researchers time and resources, The Michael J. Fox Foundation has made a number of tools available to the scientific community at low cost, with rapid delivery.
Helpful Resources
-
Sponsored Tools Program
Learn more about how MJFF can help share your tools.
-
Tools Consortium
MJFF is working with industry to develop priority tools.
-
Preclinical Models
Learn more about the various in vivo models used in Parkinson's disease research.
Find a Research Tool
Filter by Tool Type or Gene/Protein Type to Organize Results
* = MJFF does not control pricing or terms of availability for this tool.
Filters
PARP1 Edited iPSC Lines
Human iPS Cell
KOLF2.1J human iPSC line with CRISPR-engineered mutations heterozygous and homozygous knockout of PARP1. This cell line development project is part of the MJFF Targets to Therapies (T2T) Initiative. Anticipated Availability: Q4 2026
LRRK2/GBA Edited iPSC Lines
Human iPS Cell
KOLF2.1J human iPSC line with CRISPR-engineered LRRK2 G2019S (heterozygous and homozygous) and GBA1 N370S (heterozygous and homozygous).These lines were generated within the iPSC Neurodegeneration Initiative for Parkinson’s Disease (iNDI-PD) which is supported by the Aligning Science Across Parkinson’s (ASAP) Initiative.Anticipated Availability: Q4 2026
SLC18B1 Edited iPSC Lines
Human iPS Cell
KOLF2.1J human iPSC line with CRISPR-engineered mutations in SLC18B1, including - S30P (heterozygous and homozygous) - in development, est late 2026
- Knockout (homozygous) - in development, est late 2026
GRN Edited iPSC Lines
Human iPS Cell
KOLF2.1J human iPSC line with CRISPR-engineered mutations in TMEM175, including - -A9D (heterozygous and homozygous) - in development, est late 2025
- -Q125X (heterozygous and homozygous)
- -R493X (heterozygous and homozygous)
MAPT Edited iPSC Lines
Human iPS Cell
KOLF2.1J human iPSC line with CRISPR-engineered mutations in TMEM175, including heterozygous knockout.These lines were generated within the iPSC Neurodegeneration Initiative for Parkinson’s Disease (iNDI-PD). This cell line development project is part of the MJFF Targets to Therapies (T2T) Initiative. Estimated Availability: Late 2026
NOD2 Edited iPSC Lines
Human iPS Cell
KOLF2.1J human iPSC line with CRISPR-engineered mutations in NOD2, including heterozygous and homozygous knockout.These lines were generated within the iPSC Neurodegeneration Initiative for Parkinson’s Disease (iNDI-PD) which is supported by the Aligning Science Across Parkinson’s (ASAP) Initiative. Estimated Availability: late 2025
LRRK2 Edited iPSC Lines
Human iPS Cell
KOLF2.1J human iPSC line with CRISPR-engineered mutations in LRRK2, including: - -R1298H (heterozygous and homozygous) - in development, est late 2025
- -R1441C (heterozygous and homozygous)
- -R1441G (heterozygous and homozygous)
- -R1628H (heterozygous and homozygous) - in development, est late 2025
- -Y1699C (heterozygous and homozygous)
- -L1795F (heterozygous and homozygous) - in development, est late 2025
- -G2019S (heterozygous and homozygous)
- -I2020T (heterozygous and homozygous)
- -N2081D (heterozygous and homozygous)
- -G2385R (heterozygous and homozygous) - in development, est late 2026
PPM1M Edited iPSC Lines
Human iPS Cell
KOLF2.1J human iPSC line with CRISPR-engineered mutations in PPM1M, including - -D440N (heterozygous and homozygous) - in development, est late 2026
- -Knockout (homozygous) - in development, est late 2026
PSMF1 Edited iPSC Lines
Human iPS Cell
KOLF2.1J human iPSC line with CRISPR-engineered mutations in PSMF1, including - -R231* (heterozygous and homozygous) - in development, est late 2025
- -R242C (heterozygous and homozygous) - in development, est late 2025
- -Knockout (homozygous) - in development, est late 2025
OMP25 Edited Mito-IP iPSC Line
Human iPS Cell
KOLF2.1J human iPSC line with DOX-NGN2 + HA-tagged OMP25 for Mito-IP.These lines were generated within the iPSC Neurodegeneration Initiative for Parkinson’s Disease (iNDI-PD). Cell line development is also supported by MJFF Targets to Therapies (T2T) Initiative. Estimated Availability: late 2026
Have questions or need additional information?
Email tools@michaeljfox.org with questions and to suggest new tools for us to develop. Or visit our FAQ page.
"We have shown, thanks in part to MJFF, that researchers now have in their pantry the right ‘ingredients’, to... help to drive forward PD drug development.”
Heather Melrose, PhD
Mayo Clinic